Cargando…

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

BACKGROUND: Less than one-third of patients who are estimated to be infected with multidrug-resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of those who received treatment have successful outcomes. Despite current regimens, newer, more effective and cost-effective app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xiaoyan, Smare, Caitlin, Kambili, Chrispin, El Khoury, Antoine C., Wolfson, Lara J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267460/ https://www.ncbi.nlm.nih.gov/pubmed/28122562 http://dx.doi.org/10.1186/s12913-016-1931-3

Ejemplares similares

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
por: Agnarson, Abela Mpobela, et al.
Publicado: (2020)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Emergence of bedaquiline resistance in a high tuberculosis burden country
por: Chesov, Elena, et al.
Publicado: (2022)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study
por: Kurosawa, Ken, et al.
Publicado: (2021)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
por: Deshkar, Anuradha T, et al.
Publicado: (2022)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
por: Kang, Yewon, et al.
Publicado: (2022)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Bedaquiline versus placebo for management of multidrug-resistant tuberculosis: A systematic review
por: Singh, Surjit, et al.
Publicado: (2016)

Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
por: Trevisi, Letizia, et al.
Publicado: (2023)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial
por: Meyvisch, Paul, et al.
Publicado: (2018)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
por: Shao, Ge, et al.
Publicado: (2023)

Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug
por: Jain, Nirmal Kumar
Publicado: (2022)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China
por: Zou, Jin, et al.
Publicado: (2022)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Effects of Bedaquiline on Antimicrobial Activity and Cytokine Secretion of Macrophages Infected with Multidrug-Resistant Mycobacterium tuberculosis Strains
por: Lyu, Xia-Li, et al.
Publicado: (2022)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
por: Li, Rong, et al.
Publicado: (2023)

Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2020)

Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report
por: De Vito, Andrea, et al.
Publicado: (2022)

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
por: Shim, Tae Sun, et al.
Publicado: (2023)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
por: Wu, Sheng-Han, et al.
Publicado: (2021)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j05htjmoc3cafmflm4i5egffsc